MSMrinali Shetty

Mrinali Shetty

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mrinali Shetty has a total of 114 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew J. Einstein

    Division of Cardiology, Department of Medicine, and Department of Radiology, Columbia University Irving Medical Center and New York-Presbyterian Hospital (A.J.E.).

    5 shared publications
  • Yosef A. Cohen

    Seymour, Paul and Gloria Milstein Division of Cardiology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York; Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York; Department of Pediatrics, Montefiore Medical Center, Bronx

    4 shared publications
  • Kevin J. O'GOrman

    Department of Medicine, Uniformed Services University F. Edward Hébert School of Medicine, Bethesda, MD, United States; Seymour, Paul and Gloria Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and New York-Presbyterian Hospital, New York, NY, United States

    2 shared publications
  • Michelle Castillo

    Seymour, Paul and Gloria Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, NY, United States

    2 shared publications
  • Nishant R. Shah

    Division of Cardiology, Department of Medicine, Brown University Alpert Medical School, Providence, RI, USA

    2 shared publications
  • Adam Bernheim

    From the Department of Radiology, Children’s National Hospital, Washington, DC (D.B.); Department of Radiology and Imaging Sciences (E.A.B.) and Department of Medicine, Division of Pulmonary and Critical Care Medicine (S.V.), Emory University, Atlanta, Ga; Department of Radiology, Massachusetts General Hospital, Boston, Mass (A.S., J.B.A., B.P.L.); and Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (A.B., M.C.).

    1 shared publication

Latest Publications

  • Use of Advanced Coronary Artery Disease Imaging Within Veterans Affairs Facilities Compared to Medicare Beneficiaries

    by Yosef A. Cohen, Nishant R. Shah, Kevin J. O'GOrman, Mrinali Shetty, David E. Winchester, Andrew J. Einstein

  • Normal Values for 13N-Ammonia PET-derived Metrics in Heart Transplant Patients

    by Kevin J. O’GOrman, Luca Bremner, Zayd Mian, Lee Yang, Mrinali Shetty, Yosef A. Cohen, Megha Prasad, Hannah R. Rosenblum, Matthew K. Hoffman, Srilaxmi Bearelly, et al.

  • Temporal Trends in Noninvasive and Invasive Cardiac Testing From 2010 to 2022 in the US Medicare Population

    by Yosef A. Cohen, Luca Bremner, Mrinali Shetty, Michelle Castillo, Julia Susan Cappell, Jay S. Leb, Lynne L. Johnson, Andrew J. Einstein

    BACKGROUND: Cardiac diagnostic testing continues to evolve, and controversies remain regarding the optimal utilization of different procedures. We sought to evaluate changes in long-term utilization trends for a wide range of cardiac diagnostic tests in the context of advancing technologies and updated guidelines. METHODS: Annual cardiac testing volumes from 2010 to 2022 in the Medicare Part B population were compared across tests and by provider specialty and analyzed using Joinpoint regression. RESULTS: The most-utilized test in the Medicare population remained transthoracic echocardiography, accounting for 61.5% of cardiac testing use in 2011 and 67.7% in 2022, followed by single-photon emission computed tomography (CT) myocardial perfusion imaging, which decreased from 20.8% to 12.9%. Single-photon emission CT myocardial perfusion imaging use decreased relative to positron emission tomography myocardial perfusion imaging (ratio of 39:1 in 2011 to 7:1 in 2022), stress cardiac magnetic resonance (1179:1 in 2011, 268:1 in 2022), and coronary CT angiography (61:1 in 2011, 10:1 in 2022). Decreased use was also observed for exercise treadmill testing (2.3% to 1.7%), stress echocardiography (3.6% to 2.6%), multigated acquisition (0.4% to 0.1%), and invasive coronary angiography (8.0% to 7.0%). The use of fractional flow reserve by CT per 100 000 Medicare enrollees increased by >16-fold from 2018 (the first year covered) to 2022, and cardiac amyloidosis pyrophosphate scintigraphy studies increased 4-fold from 2011 to 2022 (0.17% to 0.68%). Positron emission tomography myocardial perfusion imaging volumes have surpassed exercise treadmill test volumes and, assuming the current rate of change continues, are projected to surpass stress echocardiography volumes in 2024. Coronary CT angiography is projected to overtake exercise treadmill testing in 2024 and stress echocardiography in 2025. CONCLUSIONS: Between 2010 and 2022, cardiac diagnostic testing in the US Medicare population shifted from invasive angiography and traditional stress testing toward an increase in cardiac CT, cardiac magnetic resonance, and positron emission tomography. Pyrophosphate scintigraphy studies also increased, as did fractional flow reserve by CT since its introduction. Changes in preferred diagnostic modalities suggest a need to reevaluate current recommendations for training in cardiovascular medicine.


  • Open Access

    Tobacco Use, Electronic Nicotine Delivery Systems, and Vulnerable Populations

    by Mohammed Abozenah, Noreen T. Nazir, Nishtha Sareen, Eric Brandt, Quinn R. Pack, Uzoma Ibebuogu, Mrinali Shetty, Kavisha Singh, Eric C. Stecker, Eugene Yang


  • Cardiovascular Testing in the United States during the COVID-19 Pandemic: Volume Recovery and Worldwide Comparison

    by Cole B. Hirschfeld, Sharmila Dorbala, Leslee J. Shaw, Todd C. Villines, Andrew D. Choi, Nathan Better, Rodrigo J. Cerci, Ganesan Karthikeyan, Michelle C. Williams, Mouaz Al-Mallah, et al.

    To characterize the recovery of diagnostic cardiovascular procedure volumes in U.S. and non-U.S. facilities in the year following the initial COVID-19 outbreak. The International Atomic Energy Agency (IAEA) coordinated a worldwide study called the IAEA Noninvasive Cardiology Protocols Study of COVID-19 2 (INCAPS COVID 2), collecting data from 669 facilities in 107 countries, including 93 facilities in 34 U.S. states, to determine the impact of the pandemic on diagnostic cardiovascular procedure volumes. Participants reported volumes for each diagnostic imaging modality used at their facility for March 2019 (baseline), April 2020, and April 2021. This secondary analysis of INCAPS COVID 2 evaluated differences in changes in procedure volume between U.S. and non-U.S. facilities and among U.S. regions. Factors associated with return to prepandemic volumes in the United States were also analyzed in a multivariable regression analysis. Reduction in procedure volumes in April 2020 compared with baseline was similar for U.S. and non-U.S. facilities (−66% vs −71%, P = .27). U.S. facilities reported greater return to baseline in April 2021 than did all non-U.S. facilities (4% vs −6%, P = .008), but there was no evidence of a difference when comparing U.S. facilities with non-U.S. high-income country (NUHIC) facilities (4% vs 0%, P = .18). U.S. regional differences in return to baseline were observed between the Midwest (11%), Northeast (9%), South (1%), and West (−7%, P = .03), but no studied factors were significant predictors of 2021 change from prepandemic baseline. The reductions in cardiac testing during the early pandemic have recovered within a year to prepandemic baselines in the United States and NUHICs, while procedure volumes remain depressed in lower-income countries. Keywords: SPECT, Cardiac, Epidemiology, Angiography, CT Angiography, CT, Echocardiography, SPECT/CT, MR Imaging, Radionuclide Studies, COVID-19, Cardiovascular Imaging, Diagnostic Cardiovascular Procedure, Cardiovascular Disease, Cardiac Testing Supplemental material is available for this article. © RSNA, 2023


  • Open Access

    Chemotherapy induced right ventricular cardiomyopathy; a systematic review and meta-analysis

    by Pramod Theetha Kariyanna, Ashish Kumar, Amog Jayarangaiah, Mrinali Shetty, Yuvraj Chowdhury, Sushruth Das, Apoorva Jayarangaiah

    Background: Left ventricular dysfunction and cardiomyopathy are well documented adverse effects associated with chemotherapy agents. Limited information exists regarding the impact of chemotherapeutic agents on the integrity and function of the right ventricle (RV).Objectives: The current metanalysis compared pre- chemotherapy versus post- chemotherapy RV parameters measured on 2D echocardiography in patients receiving anthracycline and/or trastuzumab across all breast cancer patients.Methods: A systematic search across PubMed, EMBASE and Cochrane databases were performed from inception of the databases until November 2021 for relevant studies. We used the inverse variance method with a random effect model and DerSimonian and Laird method of Tau2 generation to calculate mean difference [MD] with 95% confidence interval [CI]. The analysis was carried out using RevMan Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).Results: Fifteen studies, constituting total of 644 patients, met the inclusion criteria, with most studies having a follow up period of less than 12 months from initiation of chemotherapy. Anthracycline and/or Trastuzumab chemotherapy resulted in a statistically significant reduction in right ventricular ejection fraction (RVEF) at follow-up [MD: 2.70, 95% CI: 0.27 to 5.13, P-value- 0.03, I2- 71%, χ2P-value < 0.05]. Treatment with Anthracycline and/or Trastuzumab chemotherapy resulted in a significant reduction in RV fractional area change (RVFAC) at follow-up [MD: 3.74, 95% CI: 1.33 to 6.15, P-value < 0.01, I2- 68%, χ2P-value < 0.05]. RV free wall longitudinal strain (RVFWLS) was lower at baseline, while LVEF was significantly reduced at follow-up [MD: -1.00, 95% CI: -1.86 to -0.15, P-value < 0.05, I2- 0%, χ2P-value-0.40], [MD: 4.04, 95% CI: 2.08 to 6.01, P-value < 0.01, I2- 91%, χ2P-value < 0.05], respectively. However, treatment with Anthracycline and/or Trastuzumab chemotherapy had no statistically significant effect on Tricuspid annular plane systolic excursion (TAPSE) at follow-up [MD: 0.53, 95% CI: -0.11 to 1.17, P-value-0.11, I2- 98%, χ2P-value < 0.05].Conclusions: Chemotherapy with anthracyclines and trastuzumab negatively affects right ventricular function leading to decline in RVEF, RVFAC, RVFWLS and LVEF.


  • Gene Silencing Therapy in Hereditary (Variant) Transthyretin Cardiac Amyloidosis: A Puzzling Case of Decreasing Pyrophosphate Uptake on Scintigraphy

    by Dia A. Smiley, Andrew J. Einstein, Akiva Mintz, Mrinali Shetty, Nicholas Chan, Stephen T. Helmke, Ketan Bhatia, Kim Goldner, Thomas H. Brannagan, Denisse D. Santana, et al.


  • Open Access

    Impact of Social Media and Multimedia Platforms

    by Estefania Oliveros, Yevgeniy Brailovsky, Alessandro Beneduce, Hooman Bakhshi, Edoardo Zancanaro, Indah Sukmawati, Mrinali Shetty, Gina Lundberg


  • Open Access

    Iatrogenic Atrial Septal Defect Closure Following Mitral Transcatheter Edge-to-Edge Repair

    by Mrinali Shetty, Mark B. Lampert, Justin Levisay, John P. Erwin, Mark J. Ricciardi